# RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

> **NCT02871843** · PHASE1 · COMPLETED · sponsor: **EpicentRx, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Glioblastoma
- Oligodendroglioma
- Anaplastic Oligodendroglioma

## Interventions

- **DRUG:** RRx-001 dose escalation with TMZ + RT
- **RADIATION:** Radiation
- **DRUG:** Fixed dose Temozolomide (75 mg/m2)
- **DRUG:** TMZ Maintenance

## Key facts

- **NCT ID:** NCT02871843
- **Lead sponsor:** EpicentRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-14
- **Primary completion:** 2019-10-11
- **Final completion:** 2021-09-19
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871843, "RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02871843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*